EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor

Basit Öğe Kaydı
dc.authoridGORUR, Sadik/0000-0002-3458-5428
dc.authoridDUMAN, Taskin/0000-0002-6552-4193
dc.contributor.authorOkuyucu, Esra E.
dc.contributor.authorGuven, Oguz
dc.contributor.authorDuman, Taskin
dc.contributor.authorGorur, Sadik
dc.contributor.authorMelek, Ismet M.
dc.contributor.authorAkcin, Soner
dc.contributor.authorYilmazer, Serkan
dc.date.accessioned2024-09-18T20:59:15Z
dc.date.available2024-09-18T20:59:15Z
dc.date.issued2009
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective: Tadalafil is a selective phosphodiesterase type 5 (PDE-5) inhibitor approved for the treatment of erectile dysfunction. Less is known about the electroencephalography (EEG) effects of PDE-5 inhibitors, and the present study, therefore, examined the risk of EEG abnormalities associated with tadalafil. Method: EEG recordings from 35 erectile dysfunction patients taking tadalafil (20 mg) were graded for severity of EEG abnormalities (at admission, 2 and 48 hours after tadalafil administration). Results: At admission, there were no EEG abnormalities. At second EEG, abnormalities occurred in 12 (34.3%) of the 35 patients. Eight (22.9%) patients had mild and four (11.4%) patients had moderate EEG abnormalities. At third EEG, one (2.9%) patient had mild and one (2.9%) patient had moderate EEG abnormalities. Conclusion: PDE-5 inhibitors may produce EEG abnormalities. Although the exact role of PDE in altering susceptibility to seizure remains unclear, epileptic seizures may occur during treatment with PDE inhibitors. [Neurol Res 2009; 31: 313-315]en_US
dc.identifier.doi10.1179/174313209X382548
dc.identifier.endpage315en_US
dc.identifier.issn0161-6412
dc.identifier.issn1743-1328
dc.identifier.issue3en_US
dc.identifier.pmid19036180en_US
dc.identifier.scopus2-s2.0-65749096748en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage313en_US
dc.identifier.urihttps://doi.org/10.1179/174313209X382548
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12482
dc.identifier.volume31en_US
dc.identifier.wosWOS:000265960300017en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofNeurological Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTadalafilen_US
dc.subjectphosphodiesterase type 5 inhibitoren_US
dc.subjectelectroencephalographyen_US
dc.titleEEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitoren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
69.65 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu